New funding from Breast Cancer Now supports research on treatment-resistant ER-positive breast cancer

Researchers are investigating how the most common type of breast cancer resists hormone therapy, thanks to new funding from Breast Cancer Now.

Biogen’s full Ph2 data for IgA nephropathy drug; Sanofi invests in obesity biotech

Plus, news about Novartis, CombiGene, ProQR and Aardvark Therapeutics: Biogen presents full Phase 2 data for felzartamab: The drug, which was acquired in Biogen’s …

October 29, 2024

Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new

December 18, 2023

Intermittent fasting with protein pacing trumps calorie restriction in gut health and weight loss

A recent study in Nature Communications found that intermittent fasting with protein pacing (IF-P) is more effective than continuous calorie restriction (CR) in improving gut

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.